Edetic Acid

Edetic Acid

SCHEMBL537771

O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.[KH].[KH].[KH]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.93
EYA2 O00167 1/20 0.93
APP P05067 1/20 0.93
ACE P12821 1/20 0.93
BLM P54132 2/20 0.88
PMP22 Q01453 2/20 0.88
TSHR P16473 2/20 0.88
KDM4E B2RXH2 2/20 0.88
ALOX15 P16050 2/20 0.88
LMNA P02545 1/20 0.88
CHRM2 P08172 1/20 0.88
ADRA2A P08913 1/20 0.88
DRD1 P21728 1/20 0.88
SLC6A2 P23975 1/20 0.88
SLC6A4 P31645 1/20 0.88
CYP2C19 P33261 1/20 0.88
ADRA1A P35348 1/20 0.88
DRD3 P35462 1/20 0.88
SLC6A3 Q01959 1/20 0.88
HRH3 Q9Y5N1 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Edetic Acid SCHEMBL4287868 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL1007448 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL120660 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL59497 1.00 TDP1 (0.93) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL1512912 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL21483279 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL4956709 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL21483277 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL7209772 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM
Edetic Acid SCHEMBL1535300 0.97 TDP1 (0.88) TDP1EYA2APPACEBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1730 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12484819-B2 Syringe apparatus and methods SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2025-12-02 US claimed
US-20250332118-A1 NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA LIVIONEX INC (US) 2025-10-30 US claimed
US-20250222110-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF AGE-RELATED CATARACTS LIVIONEX INC (US) 2025-07-10 US claimed
CN-119932113-A Suspension system for adeno-associated virus production 生命技术公司 2025-05-06 CN claimed
WO-2025085733-A1 METHODS AND COMPOSITIONS FOR PRESERVATION OF NUCLEIC ACIDS PREDICINE, INC. (US) 2025-04-24 WO claimed
CN-115791354-B Quality control product for sperm DNA fragmentation detection and preparation method and application thereof 苏州贝康医疗器械有限公司 2025-04-18 CN claimed
WO-2025036330-A1 RNA PRESERVATION SOLUTION AND USE THEREOF 中国海关科学技术研究中心 2025-02-20 WO claimed
CN-119455604-A Phase change absorbent for natural gas desulfurization and decarbonization and preparation method thereof 陕西驭腾化学控股发展有限公司 2025-02-18 CN claimed
EP-4504163-A1 NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA Livionex, Inc. (US) 2025-02-12 EP claimed
CN-115449539-B Inactivating preservation solution for keeping virus particles intact and detection test tube 宁波市第一医院 2025-02-11 CN claimed
EP-1187897-A1 DETERGENT COMPOSITIONS FOR THE REMOVAL OF COMPLEX ORGANIC OR GREASY SOILS ECOLAB INC. (US) 2002-03-20 EP claimed
US-6350251-B1 Biocidal locks BIOLINK CORPORATION 2002-02-26 US claimed
WO-2001000760-A1 DETERGENT COMPOSITIONS FOR THE REMOVAL OF COMPLEX ORGANIC OR GREASY SOILS ECOLAB INC. (US) 2001-01-04 WO claimed
US-5925366-A PERMEATION/BINDING AGENT, THIO CROSSLINKING AGENT, AND CHELATE COMPOUND REVLON CONSUMER PRODUCTS CORPORATION (US) 1999-07-20 US claimed
WO-1998006376-A1 NAIL STRENGTHENING COMPOSITIONS AND A METHOD FOR STRENGTHENING NAILS REVLON CONSUMER PRODUCTS CORPORATION (US) 1998-02-19 WO claimed
US-4595527-A Chelating agent, ethoxylated phenol or fatty alcohol or ester nonionic surfactant with HLB of 9-13, water S. C. JOHNSON & SON, INC. (US) 1986-06-17 US claimed
US-4530781-A Metastable prespotting composition S. C. JOHNSON & SON, INC. (US) 1985-07-23 US claimed
EP-0137475-A2 Aqueous laundry prespotting composition S.C. JOHNSON & SON, INC. (US) 1985-04-17 EP claimed
EP-0137474-A2 Metastable prespotting composition S.C. JOHNSON & SON, INC. (US) 1985-04-17 EP claimed
US-4138367-A IMPREGNATING CARRIER WITH A COMPLEX OF A SLAT OF EDTA AND A PLATINUM GROUP METAL, BAKING IN STEAM NISSAN MOTOR COMPANY, LIMITED (JP) 1979-02-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332118-A1 NOVEL ORAL CARE FORMULATIONS FOR TREATMENT OF XEROSTOMIA STOM, TAS2R40, SLC14A1 TDP1 228/4885EYA2 1778/4885APP 4586/4885
US-20250222110-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF AGE-RELATED CATARACTS MSMO1, SLC16A8, SMS TDP1 3882/4885EYA2 279/4885APP 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.